New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
10:26 EDTCRUS, ATHN, SKX, SWKS, CMG, IRBT, CROX, PBYI, INOOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI UVXY CROX IRBT CMG SWKS SKX ATHN CRUS
News For INO;PBYI;CROX;IRBT;CMG;SWKS;SKX;ATHN;CRUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 21, 2015
16:06 EDTIRBTiRobot reports Q1 EPS 16c, consensus 10c
Reports Q1 revenue $118M, consensus $115.98M.
16:03 EDTCMGChipotle sees FY15 comp restaurant sales growing low-to-mid single digit
Subscribe for More Information
16:02 EDTCMGChipotle reports Q1 EPS $3.88, consensus $3.66
Subscribe for More Information
15:28 EDTCMGNotable companies reporting after market close
Subscribe for More Information
13:52 EDTCMGChipotle April weekly 697 straddle priced for 6.9% movement into Q1
Subscribe for More Information
13:47 EDTCMGChipotle technical view ahead of earnings
Subscribe for More Information
08:41 EDTCMGOptions expected to be active
Options expected to be active: UA TEVA PRGO MYL UTX QCOM VMW HOG CMG IBM VZ
06:52 EDTCMGChipotle volatility elevated into Q1 and outlook
Subscribe for More Information
05:33 EDTINOInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
April 17, 2015
07:04 EDTSKXSkechers May volatility elevated into Q1 and outlook
Subscribe for More Information
April 16, 2015
15:37 EDTCMGChipotle volatility elevated into Q1 and outlook
Subscribe for More Information
10:00 EDTCMGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
April 15, 2015
17:25 EDTCMGChipotle initiated with a Buy at Guggenheim
Subscribe for More Information
11:28 EDTSKXSkechers May volatility elevated into Q1 and outlook
Skechers May option implied volatility is at 45, June is at 37, July is at 37; compared to its 26-week average of 39 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 20.
10:00 EDTCMGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:42 EDTCMGChipotle near-term outlook positive, says Oppenheimer
Subscribe for More Information
06:04 EDTCMGChipotle initiated with an Outperform at Cowen
Subscribe for More Information
April 14, 2015
17:02 EDTCROXCrocs appoints Coach International Group president Ian Bickley to board
Subscribe for More Information
11:07 EDTATHNathenahealth volatility elevated into Q1 and outlook
athenahealth April call option implied volatility is at 62, April weekly is at 41, May is at 47, June is at 38; compared to its 26-week average of 38 according to Track Data, suggesting large price movement into the expected release of Q1 results on May 1.
08:46 EDTPBYIPuma Biotechnology expands cohort in Phase II PB272 trial
Puma Biotechnology has expanded the second cohort from its Phase II clinical trial of its lead drug candidate PB272 as a single agent in patients with solid tumors who have an activating HER2 mutation. The cohort that has been expanded is the cohort that includes patients with metastatic non-small cell lung cancer and whose tumors have a HER2 mutation. The Phase II basket trial, which was initiated in October 2013, is an open-label, multicenter, multinational study to evaluate the safety and efficacy of PB272 administered daily to patients who have solid tumors with activating (driver) ERBB mutations, including epidermal growth factor receptor, HER2 and HER3. The cohorts (baskets) included in the study are (1) bladder/urinary tract cancer; (2) breast cancer; (3) colorectal cancer; (4) endometrial cancer; (5) gastric/esophageal cancer; (6) ovarian cancer; (7) all other solid tumors with a HER2 mutation; (8) EGFR mutated and/or amplified primary brain cancer; and (9) solid tumors with a HER3 mutation. The non-small cell lung cancer patients initially entered the study in the “other solid tumors with a HER2 mutation” basket and due to the preliminary activity seen in the trial the Company has expanded the basket, as per the protocol for the trial. The expanded HER2 mutant NSCLC basket will now enroll a total of 18 patients.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use